The recent FDA approval of floretyrosine F 18 (18F-FET) marks an important milestone for molecular imaging of gliomas in the United States. FET PET imaging provides molecular information that complements conventional anatomic imaging and can help address one of the most challenging questions in glioma care: distinguishing recurrent or progressive disease from treatment-related change.
The approval is especially meaningful to UCSF. Prospective clinical trial data generated at UCSF helped support the FDA approval.
UCSF is bringing together experts from across the glioma and molecular imaging communities for the Imaging in Neuro-Oncology Conference to discuss advances in imaging in gliomas with a focus on FET PET.
The objectives of the conference are to:
- Provide background on gliomas from neurosurgery, neuro-oncology and radiation oncology.
- Review the role of MRI in glioma imaging and limitations for imaging of recurrent tumor.
- Discuss FET PET including appropriate use and interpretation.
- Review FET PET in action during a multidisciplinary tumor board.
- Look forward to future advances and applications of FET PET.
